Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Romidepsin: Interim Phase I/II data

Interim data from an open-label Phase I/II trial in 10 evaluable patients showed an

Read the full 143 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE